Market Access
British pound coins and two yellow and blue pills

Missing metrics on the UK’s VPAG

It's hard to take stock of what’s happening operationally with the UK's main pricing scheme, VPAG, given the absence of reporting by the DHSC.

Sales & Marketing

Sales & Marketing
12 questions with Jim Sage
Sponsored

12 Questions with Jim Sage

Jim Sage is a seasoned global pharmaceutical executive with extensive marketing, commercial, and leadership experience across major therapeutic areas.

Digital

Market Access

Editor's Picks

  1. UK and US agree zero tariffs on pharma – with price rises
  2. FDA clears trial of 'vectorised' ALS antibody from VectorY
  3. Tracy Beth Hoeg will be fifth CDER head this year
  4. FDA takes steps to limit non-human primate testing
  5. FDA could hike user fees for ex-US drug programmes

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more